]>
IRCT20200404046937N5 IRCT 2020-10-14 Ahvaz University of Medical Sciences Effect of remdesivir in COVID-19 Evaluation of the therapeutic effect of Remdesivir on COVID-19 patients, A single-arm clinical trial study 2020-09-27 anticipated 50 Complete https://irct.ir/trial/51178 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2-3 COVID-19. Intervention group: Patients in the main group recived Remdesivir consisting of two 100 mg vials, ie 200 mg intravenously, which is infused over a period of 30 minutes to two hours, on the first day of treatment with followed by 100 mg daily on the second, third, fourth and fifth day. Each vial is prepared with 19 cc of distilled water and diluted with 0.9% saline. Patients will be monitored daily and at the end of the 5-day treatment period. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Roohangiz Nashibi
Razi hospital, Felestin Ave, Amanieh Ave
Ahvaz Iran (Islamic Republic of) 6196514941 +98 61 3333 7446 dr.r.nashibi@ajums.ac.ir Ahvaz University of Medical Sciences scientific Mehran Varnasseri
Razi hospital, Felestin Ave, Amanieh ave
Ahvaz Iran (Islamic Republic of) 6196514941 +98 61 3333 7446 drvarnasseri.m@gmail.com Ahvaz University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Age ≥18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Severe pulmonary involvement in imaging that progresses despite receiving standard treatment protocols within 72 hours of starting antiviral therapy Oxygen saturation less than 90% with canola nasal or respiratory rate more than 30 18 years no limit Both Treatment with other antiviral drugs not listed in the national protocol Comorbidities such as malignancy, advanced heart failure, cirrhosis, dialysis patients, stroke, Alzheimer's, advanced neurological disease, progressive respiratory disease Allergic reaction to Remdesivir Pregnant or lactating women Possibility of transfer to another hospital that does not have access to study drugs Evidence of multiple organ failure Receive any experimental treatment for Covid 19 Patients under mechanical ventilation at the beginning of the study Alanine Aminotransferase or Aspartate Aminotransferase more than 5 times normal Creatinine clearance less than 50 ml per minute U07.1 Corona virus infection, unspecified Treatment - Drugs Intervention group: Patients in the main group recived Remdesivir consisting of two 100 mg vials, ie 200 mg intravenously, which is infused over a period of 30 minutes to two hours, on the first day of treatment with followed by 100 mg daily on the second, third, fourth and fifth day. Each vial is prepared with 19 cc of distilled water and diluted with 0.9% saline. Patients will be monitored daily and at the end of the 5-day treatment period Length of stay. Timepoint: The first day and the last day of the patient's hospitalization. Method of measurement: patient file. Oxygen Saturation. Timepoint: Daily. Method of measurement: Pulls oximeter. Fever. Timepoint: Daily. Method of measurement: Thermometer. Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file. Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file. Respiratory Rate. Timepoint: Daily. Method of measurement: Patients interview and patient file. C-Reactive protein. Timepoint: The first day and the seventh day of study. Method of measurement: Agglutination kit. Lymphocyte blood count. Timepoint: The first day and the seventh day of study. Method of measurement: Cell counter. Alanine Amino Transferase. Timepoint: The first day and the seventh day of study. Method of measurement: Determination of enzyme in serum by biochemical method. Aspartate Aminotransferase. Timepoint: The first day and the seventh day of study. Method of measurement: Determination of enzyme in serum by biochemical method. Ahvaz University of Medical Sciences Approved 2020-09-22 Ethics committee of Ahvaz University of Medical Ethics committee, main building, Ahvaz University of medical science, Golestan Ahvaz Khouzestan Iran (Islamic Republic of)